Marshall Paul 4

Accession 0001264124-12-000195

CIK 0000881464other

View on SEC.gov Company Profile

Filed

Aug 9, 8:00 PM ET

Accepted

Aug 10, 6:38 PM ET

Size

39.1 KB

Accession

0001264124-12-000195

Insider Transaction Report

Form 4

Period: 2012-08-08

AMYLIN PHARMACEUTICALS INCAMLN

Marshall Paul

VP Operations

Transactions

Other
Incentive Stock Option (right to buy)
2012-08-08$31.00/sh−5,597$173,507→ 0 total
Exercise: $9.02Exp: 2016-03-04→ Common Stock (5,597 underlying)
Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−89,403$2,771,493→ 0 total
Exercise: $9.02Exp: 2016-03-04→ Common Stock (89,403 underlying)
Other
Incentive Stock Option (right to buy)
2012-08-08$31.00/sh−7,145$221,495→ 0 total
Exercise: $24.87Exp: 2015-03-04→ Common Stock (7,145 underlying)
Expiration (Short)
Incentive Stock Option (right to buy)
2012-08-08−10,596→ 0 total
Exercise: $37.75Exp: 2016-12-18→ Common Stock (10,596 underlying)
Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−82,447$2,555,857→ 0 total
Exercise: $16.02Exp: 2019-03-06→ Common Stock (82,447 underlying)
Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−42,855$1,328,505→ 0 total
Exercise: $24.87Exp: 2015-03-04→ Common Stock (42,855 underlying)
Expiration (Short)
Non-Qualified Stock Option (right to buy)
2012-08-08−29,404→ 0 total
Exercise: $37.75Exp: 2016-12-18→ Common Stock (29,404 underlying)
Other
Common Stock
2012-08-08$31.00/sh−1,631.9$50,589→ 473.3 total(indirect: By 401(k))
Other
Common Stock
2012-08-08$31.00/sh−473.3$14,672→ 0 total(indirect: By 401(k))
Other
Common Stock
2012-08-08$31.00/sh−4,984.3$154,513→ 2,990.1 total(indirect: by ESOP)
Other
Incentive Stock Option (right to buy)
2012-08-08$31.00/sh−7,553$234,143→ 0 total
Exercise: $16.02Exp: 2019-03-06→ Common Stock (7,553 underlying)
Other
Common Stock
2012-08-08$31.00/sh−31,723$983,413→ 0 total
Other
Common Stock
2012-08-08$31.00/sh−2,990.1$92,693→ 0 total(indirect: by ESOP)
Other
Incentive Stock Option (right to buy)
2012-08-08$31.00/sh−11,069$343,139→ 0 total
Exercise: $10.53Exp: 2018-09-20→ Common Stock (11,069 underlying)
Other
Incentive Stock Option (right to buy)
2012-08-08$31.00/sh−6,904$214,024→ 0 total
Exercise: $18.01Exp: 2017-02-02→ Common Stock (6,904 underlying)
Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−23,931$741,861→ 0 total
Exercise: $10.53Exp: 2018-09-20→ Common Stock (23,931 underlying)
Other
Non-Qualified Stock Option (right to buy)
2012-08-08$31.00/sh−63,096$1,955,976→ 0 total
Exercise: $18.01Exp: 2017-02-02→ Common Stock (63,096 underlying)
Other
Performance Shares
2012-08-08$31.00/sh−30,000$930,000→ 0 total
→ Common Stock (30,000 underlying)

Footnotes (5)

[F1]Represents a sale of shares to B&R Acquisition Company, a wholly-owned subsidiary of Bristol-Myers Squibb Company, either through directly tendering such shares or by virtue of a sale in the merger pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc. Includes unvested restricted stock units that were cancelled at the effective time of the merger in exchange for the right to receive cash payment for such restricted stock units at a price of $31.00 per restricted stock unit.
[F2]Represents a sale of shares to B&R Acquisition Company, a wholly-owned subsidiary of Bristol-Myers Squibb Company, either through directly tendering such shares or by virtue of a sale in the merger pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc.
[F3]Pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc., these options, whether or not vested, were cancelled at the effective time of the merger in exchange for the right to receive cash payment in the amount of $31.00 per option less the exercise price of such option.
[F4]Pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc., all options held by the reporting person with an exercise price above $31.00 per share were cancelled upon consummation of the merger.
[F5]Pursuant to the Agreement and Plan of Merger, dated as of June 29, 2012, among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc., these performance-based restricted stock units, whether or not vested, were canceled prior to consummation of the merger in exchange for the right to receive cash payment for each such restricted stock unit at a price of $31.00 per restricted stock unit.

Documents

1 file

4
edgardoc.xmlPrimary
PRIMARY DOCUMENT

Issuer

AMYLIN PHARMACEUTICALS INC

CIK 0000881464

→

Entity typeother

Related Parties

filerCIK 0001383994

Filing Metadata

Form type: 4
Filed: Aug 9, 8:00 PM ET
Accepted: Aug 10, 6:38 PM ET
Size: 39.1 KB

View on SEC.gov